Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLA Working Group of the Japan Society for Blood and Marrow

2013 ◽  
Vol 161 (4) ◽  
pp. 566-577 ◽  
Author(s):  
Yoshinobu Kanda ◽  
Junya Kanda ◽  
Yoshiko Atsuta ◽  
Yoshinobu Maeda ◽  
Tatsuo Ichinohe ◽  
...  
2014 ◽  
Vol 56 (6) ◽  
pp. e96-e98 ◽  
Author(s):  
Emiko Miyashita ◽  
Hisao Yoshida ◽  
Daisuke Mori ◽  
Natsuki Nakagawa ◽  
Takako Miyamura ◽  
...  

2020 ◽  
Vol 99 (5) ◽  
pp. 1099-1110
Author(s):  
Koji Kawamura ◽  
Junya Kanda ◽  
Kazuteru Ohashi ◽  
Takahiro Fukuda ◽  
Koji Iwato ◽  
...  

1997 ◽  
Vol 15 (2) ◽  
pp. 566-573 ◽  
Author(s):  
F Locatelli ◽  
C Niemeyer ◽  
E Angelucci ◽  
C Bender-Götze ◽  
S Burdach ◽  
...  

PURPOSE To evaluate the role of allogeneic bone marrow transplantation (BMT) in children with chronic myelomonocytic leukemia (CMML). PATIENTS AND METHODS Forty-three children with CMML given BMT and reported to the European Working Group on Myelodysplastic Syndrome in Childhood (EWOG-MDS) data base were evaluated. In 25 cases, the donor was a human leukocyte antigen (HLA)-identical or a one-antigen-disparate relative, in four cases a mismatched family donor, and in 14 a matched unrelated donor (MUD). Conditioning regimens consisted of total-body irradiation (TBI) and chemotherapy in 22 patients, whereas busulfan (Bu) with other cytotoxic drugs was used in the remaining patients. RESULTS Six of 43 patients (14%), five of whom received transplants from alternative donors, failed to engraft. There was a significant difference in the incidences of chronic graft-versus-host disease (GVHD) between children transplanted from compatible/one-antigen-mismatched relatives and from alternative donors (23% and 87%, respectively; P < .005). Probabilities of transplant-related mortality for children given BMT from HLA-identical/one-antigen-disparate relatives or from MUD/ mismatched relatives were 9% and 46%, respectively. The probability of relapse for the entire group was 58%, whereas the 5-year event-free survival (EFS) rate was 31%. The EFS rate for children given BMT from an HLA-identical sibling or one-antigen-disparate relative was 38%. In this latter group, patients who received Bu had a better EFS compared with those given TBI (62% v 11%, P < .01). CONCLUSION Children with CMML and an HLA-compatible relative should be transplanted as early as possible. Improvement of donor selection, GVHD prophylaxis, and supportive care are needed to ameliorate results of BMT from alternative donors.


1996 ◽  
Vol 47 (1-2) ◽  
pp. 80
Author(s):  
Z. Tatari ◽  
H. Espérou ◽  
C. Chastang ◽  
C. Fortier ◽  
J.C. Bensa ◽  
...  

1996 ◽  
Vol 47 (1-2) ◽  
pp. 82
Author(s):  
Jeannet Michel ◽  
Speiser Daniel ◽  
Rufer Nathalie ◽  
Grundschober Christophe ◽  
Gratwohl Alois ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document